TRK Inhibitors: Evolution of a Tumor-Agnostic Treatment Approach

TRK Inhibitors: Evolution of a Tumor-Agnostic Treatment Approach

Episodes

Specialty:

All

Year:

All

EP. 1: NTRK: An Attractive Target for Therapy

July 30th 2019

EP. 2: Larotrectinib: The First FDA-Approved TRK Inhibitor

July 30th 2019

EP. 3: Updated Data for Larotrectinib

July 30th 2019

EP. 4: Larotrectinib for NTRK Fusions: Patient Selection

July 30th 2019

EP. 5: TRK Inhibition: Personal Experience With Larotrectinib

July 30th 2019

EP. 6: Considering Available Data for Entrectinib

July 30th 2019

EP. 7: Treating Pediatric Patients With TRK Inhibitors

July 30th 2019

EP. 8: TRK Inhibition in CNS Tumors or Metastases

July 30th 2019

EP. 9: Other Approaches to TRK-Fusion Cancers

July 30th 2019

EP. 10: Envisioning Use of TRK Inhibitors in Clinical Practice

July 30th 2019

EP. 11: The Importance and Evolution of NGS Testing

July 30th 2019

EP. 12: Use of TRK Inhibition in Specific Tumor Types

July 30th 2019

EP. 13: TRK Inhibition: Future Challenges and Evolutions

July 30th 2019

Trending on OncLive

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

Updated NCCN Guidelines Recommend Rusfertide Across Polycythemia Vera

Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’